Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
Public ClinicalTrials.gov record NCT00796978. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin®) in Older Women With Early-Stage and Locally Advanced Breast Cancer: A Phase II Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying the side effects of trastuzumab and to see how well it works in treating older women with early-stage breast cancer.
Study identification
- NCT ID
- NCT00796978
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 56 participants
Conditions and interventions
Conditions
Interventions
- trastuzumab Biological
- laboratory biomarker analysis Other
- adjuvant therapy Procedure
- quality-of-life assessment Procedure
Biological · Other · Procedure
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 4, 2009
- Primary completion
- Jan 5, 2016
- Completion
- Feb 25, 2020
- Last update posted
- Apr 30, 2024
2009 – 2020
United States locations
- U.S. sites
- 11
- U.S. states
- 4
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Wake Forrest | Winston-Salem | North Carolina | 27157 | — |
| Lake/University Seidman Cancer Center | Cleveland | Ohio | 44060 | — |
| University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| University Suburban Health Center | Cleveland | Ohio | 44121 | — |
| UHHS Chagrin Highlands Medical Center | Cleveland | Ohio | 44122 | — |
| Southwest General Health Center | Cleveland | Ohio | 44130 | — |
| UHHS Westlake Medical Center | Cleveland | Ohio | 44145 | — |
| UH-Monarch | Mayfield Heights | Ohio | 44124 | — |
| Sharon Health Center | Wadsworth | Ohio | 44281 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00796978, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2024 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00796978 live on ClinicalTrials.gov.